U.K. awards $1.57 million to IAVI annually for five years
Investments from the DFID, other governments, foundations and philanthropic supporters helped the IAVI to build a comprehensive portfolio of AIDS vaccine candidates and approaches. The funding over the next five years will help IAVI to bring together experts from the pharmaceutical sector and academia to collaboratively develop and evaluate novel vaccine candidates.
The goal of the collaborative effort is to prove that at least one candidate can be fully developed into an effective vaccine to prevent HIV infection or AIDS.
"We are grateful to the U.K. government for having been a long standing partner and supporter," Margaret McGlynn, IAVI's president and CEO, said. "The government's continued trust in and financial support for IAVI will help ensure the development of preventive HIV vaccines that are safe, effective and accessible to all. Vaccines remain among our most effective and efficient tools for combating infectious diseases and can bring particular value to vulnerable populations, including women and children."
In the last 15 years, IAVI has developed partnerships and capacity for research in countries most affected by AIDS and HIV. Much of the research was coordinated by IAVI's U.K.-based laboratory at Chelsea and Warminster Hospital.
There are approximately 7,000 new HIV infections each day worldwide. There are currently 34 million people living with HIV throughout the world.